1728. Immune Responses to Cross-Reactive Serotypes 6C and 15C After 20-Valent Pneumococcal Conjugate Vaccine in Infants

BACKGROUND: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection against pneumococcal disease. PCV20 contains conjugates for serotype 6A, which is also in 13-valent PCV (PCV13) and appears to have had a clinical impact on 6C disease, and the additional serotype 15B...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamimi, Noor, Kline, Mary J, Center, Kimberly J, Thompson, Allison, Baugher, Gary, Drozd, Jelena, Scully, Ingrid L, Giardina, Peter, Trammel, James, Lei, Lanyu, Peng, Yahong, Scott, Daniel, Gruber, William C, Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679186/
http://dx.doi.org/10.1093/ofid/ofad500.1560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679186/
http://dx.doi.org/10.1093/ofid/ofad500.1560

Ejemplares similares